The efficacy and safety of Momordica charantia based on relevant studies and reviews are described. M. charantia also known as bitter melon has been proposed to exert effects in lowering blood glucose levels by means of various forms and extracts from the plant. Over the years, commercially available preparations containing bitter melon are made available in the market despite limitations on available clinical trials. Clinical trial conducted demonstrates variety in findings on the effect of M. charantia on glycemic control with mostly not exhibiting statistically significant differences. Monitoring is vital in view of the reported side effects and precaution warranted for the specific individuals and unknown herbal-drug or herbal-food interaction that could possibly interrupt the overall management plan. For the meantime, findings generated from the studies only provide implication on the potential advantages that M. charantia offers in preventing and managing type 2 diabetes as well as the microvascular complications instead of a certain conclusion.
INTRODUCTION
Within the population of Malaysia, Momordica charantia is among the traditional vegetables or generally referred to as "ulam" and is locally known as Peria Katak. [1] It is commonly consumed for its effect on blood glucose levels. [1] M. charantia or bitter melon has been suggested to produce hypoglycemic effect via utilization of various forms and extracts of the plant. [2] More than 20 brand of supplements containing M. charantia is listed and granted registration codes by the National Pharmaceutical Control Bureau. [3] Despite limitations on available published clinical trial on findings of efficacy and safety, the product is widely advertised for its hypoglycemic properties. This somehow indicates the extensive usage in our local community, which is possibly related to the increased prevalence of diabetes cases in Malaysia. [4] This brief review is conducted to evaluate the efficacy and safety of M. charantia based on relevant studies and reviews.
METHODOLOGY
An electronic search for studies on the effectiveness and safety of M. charantia was carried out from resources of MEDLINE, Cochrane Library, trial, and reviews. The relevant studies and reviews are summarized in Table 1 , inclusive of trials conducted in human, with the evaluated preparation administered orally.
PHARMACOKINETIC
Limited data are available with regard to the pharmacokinetic properties of m. Charantia. The dried powder form of the fruit, orally administered in mice, produces a peak effect at 10 h with half-life of 7.6 Min. [5] Distribution site was found highest in kidney, lung, liver, stomach, and brain.
EFFICACY IN TRIALS
In a double-blind, randomized, placebo-controlled trial that looks at the glycemic effect by the capsule formulation of M. charantia, result was inconclusive as the power achieved was only 11% even though a difference in the hemoglobin A1c (HbA1c) value was shown in the treatment group receiving M. charantia. [6] In a randomized, two-arm, parallel placebo-controlled trial on glycemic effect as well as the glycation status by the dried pulp preparation of M. charantia, findings provide preliminary evidence on the significant benefit of M. charantia in the form of dried fruit pulp in reducing levels of HbA1c up to 16 weeks. [7] In addition, decrement of total advanced glycation end products that relates to long-term complications in diabetic such as nephropathy and retinopathy implies its potential profit in preventing the associated microvascular complications.
Another randomized controlled trial assesses the potential of M. charantia as a hypoglycemic agent. [8] The administration of M. charantia at the dose used in this study as a dried whole fruit does not produce any significant effects in lowering blood sugar.
A multicenter, randomized, double-blind, active control trial by Fuangchan et al. evaluates the efficacy of bitter melon at three different dose ranges in comparison to conventional oral hypoglycemic agent -metformin in means of hypoglycemic effect. [9] Findings from the study showed that glycemic control was achievable by both metformin and bitter melon at a daily dose of 1000 mg/day and 2000 mg/day with reference to fructosamine concentrations, respectively. Nevertheless, the hypoglycemic effect of bitter melon is lesser in comparison to metformin. Study provides a base on the feasible dose of M. charantia in the form of dried powder that may be used for future studies.
A systematic review of randomized trials evaluates the effect M. charantia in type 2 diabetes patients administering oral preparations in a variety of forms and dosages. The preparations were taken alone, or concurrently with oral hypoglycemic agents, with or without insulin. [10] Having most studies not exhibiting statistically significant differences between M. charantia consumption and placebo or other medication, suggestion was made to perform more trials in providing standardization over issues and the quality control to make sound recommendations that may be placed in practice.
SAFETY
Monitoring done in studies reveals insignificant effect on tested laboratory findings including alanine aminotransferase, aspartate aminotransferase, [6, 7, 9, 11] and serum creatinine [6, 7, 11] in patients administering M. charantia of specified doses in the particular studies. Caution is somehow to be exercised for use in those with existing liver impairment or actively consuming drugs that is known to induce hepatotoxicity. [5] Report on mild side effect includes gastrointestinal [7, 11] and central nervous system [9] related. Nonetheless, they are not regarded as conclusive as length of reported studies is limited from only weeks to months. It is, however, worth to note on the more seriously reported adverse event, hypoglycemic coma and convulsions in children. [12] Precaution is as well advice in individuals with glucose-6-phosphate-dehydrogenase deficient due to the risk of favism following exposure to the seeds of M. charantia [12] and in expecting women due to risk of miscarriage. [13] With the incomplete pharmacokinetic findings, administration by patients with existing renal, liver impairment places them at risk.
Interaction is another aspect to be discussed. A minimum drug interaction data are documented on M. charantia, with most of reviews mentioning the synergistic effect when taken together with hypoglycemic agents. [14] [15] [16] Hence, patients should be educated on the danger of extreme hypoglycemic level if they were taken together improperly, regardless of form of preparation. In addition, ingestion of multiple types of herbal, may it be part of daily meal or as dietary supplement without knowing their similar pharmacological actions, further places a patient at risk by potentiating the effect of one another.
Even though clinical findings are not conclusive on the hypoglycemic effect by bitter melon, results do somehow demonstrate the blood glucose lowering effect. Synergistic effect provides idea on the claimed role, but recommendation on the required dose adjustment to prevent risk of hypoglycemic is not presented. Therefore, health care professionals should always be conscious on the possibilities of intake with the prescribed hypoglycemic agents and be able to offer evidence-based explanation particularly on the safety matters on its ingestion.
A cross-sectional study by Ching et al. revealed 62.5% prevalence on complementary and alternative usage among type 2 diabetic patients in a local setting, with bitter gourd (M. charantia) being the mostly consumed herbal based alternative. [17] They described that part of the reason on such would be the belief that these complementary medicines potentially ameliorate the diabetes condition.
The safety factor following intake of herbal-based supplements may not be a major consideration since mostly may regard them as a common "ulam" included in daily meals. Method of consumption varies from the capsule preparation to dried fruit.
Up to date, even preparations used in clinical trials are not of standardized formulation, [10] indicating that a well-formulated preparation that is effective as a hypoglycemic agent, far more in terms of safety, has not been identified yet. Thus, the various forms of bitter melon consumed, when it is not recognized, pose risk in terms of unproven efficacy against the claimed effect since available trial does not provide definitive findings. Also, risk of toxicity should be concerned about, if the doses in use are beyond the therapeutic range, that presently remains unknown. Moreover, available trials do not directly evaluate the safety outcomes with regard to the administration of bitter melon. Safety measures were mostly additional outcome in the findings.
Apart from that, description on the adverse events is limited to length of study between 4 weeks to 3 months only. [10] Having patients consuming the herbal supplements over years, [17] result for longer terms should instead be considered. Safety aspects following long-term exposure are paramount importance since diabetic itself is a chronic condition that brings about the likelihood of prolonged intake.
It is noted that most trials are conducted within Asia vicinity, possibly due to the accessibility of the herbal diversity. Thus, wide consumption may be linked to the availability in the country. Having multiple risks, prolonged use without proper monitoring may compromise the overall management plan.
RECOMMENDATION AND CONCLUSION
In all of the reviewed clinical trials, dissimilar outcome measures were used such as fasting blood glucose levels, [6, 9] HbA1c, [6, 7] and fructosamine levels. [6, 9] Furthermore, parts of the M. charantia in use also differ in all studies. This somehow renders difficulty in providing a collective assessment. As known, dietary intake and physical activities play a role in part of diabetes management that can affect glucose level. With no direct control, these confounding factors may impinge the outcome measure. Although supportive outcomes were noted in some of the studies, nevertheless, attention on the study design, duration of study, and sample size (which is mostly small) should be accounted in deriving conclusions.
Thus, further studies with larger sample, longer period, controlled environment with the use of standard preparation of the herb are needed to allow concrete conclusion to be made and placed in practice. Definite findings of dosage form and dosage in use to achieve hypoglycemic effect, safely, are also necessary. As for the meantime, findings generated from the studies only provide implication on the potential advantages that M. charantia offers in preventing and managing type 2 diabetes as well as microvascular complications instead of a certain conclusion.
Complete pharmacokinetic data in human are still unavailable. The reviewed studies recruited patients with normal kidney and liver function. Although insignificant changes were seen at the end of study periods, [7, 9] intake of preparation is not advised in patients with existing impairment until further explored.
Patients should be encouraged to report the use of this preparation as monitoring is vital in view of the precaution warranted for the specific individuals and unknown herbal-drug or herbal-food interaction that could possibly interrupt the overall management plan.
It was found that ideation on the use of these complementary medicines within the local diabetes mellitus population comes from friends, family members, and media. [17] Multimedia may be utilized for sellers of these products to reach consumers. This is inclusive of the internet that provides information and as a tool that eases availability. [18] In the local setting, healthcare providers in particular and the public are to be aware on the importance of any marketed product conforming to the guide as outlined by the Malaysia's Medicine Advertisement Board. [19] Advertisement requirement includes complete information of product to avoid ambiguity, advisory statement for continued consultation with physician to monitor blood glucose and hypoglycemic agent adjustment, owing to the risk of potentiated effect. Safety detail on the use of product should also be informed.
Advertiser holds social responsibility in avoiding misleading understanding by the public. Example of such deprivation includes the inclusion of testimonials without mentioning that the effect somehow varies between individuals and using "guaranteed" term that may delude public's estimation on the actual value of product. Until hypoglycemic effect is made evident through more reliable findings, M. charantia or bitter melon preparations from the evidence-based view should not be encouraged. Nonetheless, with continuation of intake, the preparation being in any form should only be regarded as a supplement and not an alternate to the established therapy in place with continuous monitoring.
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